ESMO 2021 | Talabostat combined with pembrolizumab in men with mCRPC

Paul Monk, MD, Ohio State University Comprehensive Cancer Center, Columbus, OH, discusses BXCL701 (talabostat), an oral small molecule inhibitor of dipeptidyl peptidases, which has been evaluated in a Phase Ib/II study in combination with pembrolizumab, in patients ith metastatic castration-resistant prostate cancer (mCRPC). Oral BXCL701 in combination with pembrolizumab demonstrates encouraging anti-tumor activity in very late-line, refractory mCRPC adenocarcinoma.This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.